| Filed On | Filing |
|---|---|
| 19 Oct 2026 |
8-K: Other Events
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform |
| 14 Aug 2026 | 10-Q |
| 15 May 2026 | 10-Q |
| 04 May 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders |
| 20 Mar 2026 | DEFA14A |
| 20 Mar 2026 | ARS |
| 20 Mar 2026 |
Proxy statement: annual meeting on May 1, 2026
say-on-pay vote |
| 19 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 18 Mar 2026 | 10-K |
| 10 Mar 2026 | FORM PRE 14A |
| 09 Feb 2026 | 8-K: Shareholder Director Nominations |
| 19 Nov 2025 |
Form 4: Knobil Katharine, Director
Granted 221,741 Stock Option (Right to Buy) |
| 19 Nov 2025 |
Form 4: Eansor Norman David, Director
Granted 221,741 Stock Option (Right to Buy) |
| 19 Nov 2025 |
Form 4: Elms Steve, Director
Granted 221,741 Stock Option (right to buy) |
| 17 Nov 2025 | SCHEDULE 13D/A |
| 14 Nov 2025 | SCHEDULE 13G/A |
| 14 Nov 2025 | 8-K: Results of Operations and Financial Condition |
| 13 Nov 2025 | 10-Q |
| 05 Nov 2025 | 8-K: Departure/Election of Directors or Officers; Compensation; Other Events |
| 04 Nov 2025 |
Form 3: Corzo Kathryn Penkus, Director
No securities owned |
Loading...
